Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)

被引：0
|
作者：
Simpkins, Fiona
Nasioudis, Dimitrios
Wethington, Stephanie L.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Torigian, Drew A.
Omran, Dalia K.
Rodriguez, Diego
Smith, Simon
Dean, Emma
Domchek, Susan M.
Drapkin, Ronny
Shih, Ie-Ming
Brown, Eric J.
Hwang, Wei-Ting
Armstrong, Deborah Kay
Gaillard, Stephanie
Giuntoli, Robert Lawrence, II
Liu, Joyce F.
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Univ Penn, Dept Radiol, Philadelphia, PA USA
[4] AstraZeneca, R&D Oncol, Royston, England
[5] AstraZeneca, R&D Oncol, Cambridge, England
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[7] Univ Penn, Dept Canc Biol, Philadelphia, PA USA
[8] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA USA
[9] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
    Mirza, Mansoor Raza
    Bergmann, Troels K.
    Mau-Sorensen, Morten
    Christensen, Rene dePont
    Avall-Lundqvist, Elisabeth
    Birrer, Michael J.
    Jorgensen, Morten
    Roed, Henrik
    Malander, Susanne
    Nielsen, Flemming
    Lassen, Ulrik
    Brosen, Kim
    Bjorge, Line
    Maenpaa, Johanna
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 791 - 798
  • [22] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
    Mansoor Raza Mirza
    Troels K. Bergmann
    Morten Mau-Sørensen
    René dePont Christensen
    Elisabeth Åvall-Lundqvist
    Michael J. Birrer
    Morten Jørgensen
    Henrik Roed
    Susanne Malander
    Flemming Nielsen
    Ulrik Lassen
    Kim Brøsen
    Line Bjørge
    Johanna Mäenpää
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 791 - 798
  • [23] A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
    Kose, MF
    Sufliarsky, J
    Beslija, S
    Saip, P
    Tulunay, G
    Krejcy, K
    Minarik, T
    Fitzthum, E
    Hayden, A
    Melemed, A
    GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 374 - 380
  • [24] PARP Inhibitor Rechallenge Could be an Effective Strategy in Platinum-Sensitive Ovarian Cancer: A Retrospective Study
    Zhong, Lin
    Wang, Haixia
    Lei, Cuirong
    Wang, Ling
    Tang, Qin
    Huang, Yiqin
    He, Misi
    Zou, Dongling
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (03): : 2609 - 2619
  • [25] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
  • [26] Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC)
    Montes, A.
    Sandhu, S. K.
    Rothermundt, C.
    Coombes, I.
    A'Hern, R.
    Keyzor, C.
    Thomas, A.
    Kaye, S.
    Gore, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
    Matulonis, Ursula
    Berlin, Suzanne
    Lee, Hang
    Whalen, Christin
    Obermayer, Elizabeth
    Penson, Richard
    Liu, Joyce
    Campos, Susana
    Krasner, Carolyn
    Horowitz, Neil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 417 - 423
  • [28] Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer
    Nakamura, Keiichiro
    Matsuoka, Hirofumi
    Yorimitsu, Masae
    Ogawa, Mariko
    Kanemori, Miho
    Sueoka, Kotaro
    Kozai, Ayumi
    Nakamura, Hiroko
    Haruma, Tomoko
    Shiroyama, Yuko
    Hayata, Yuu
    Sugii, Hirokazu
    Ueda, Akiko
    Kurihara, Shuichi
    Urayama, Saiko
    Shimizu, Miyuki
    Masuyama, Hisashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 31 - 37
  • [29] Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
    Ursula Matulonis
    Suzanne Berlin
    Hang Lee
    Christin Whalen
    Elizabeth Obermayer
    Richard Penson
    Joyce Liu
    Susana Campos
    Carolyn Krasner
    Neil Horowitz
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 417 - 423
  • [30] Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
    Majic, Ana
    Mise, Branka Petric
    Matkovic, Visnja
    Belac Lovasic, Ingrid
    Katic, Kristina
    Canjko, Ivana
    Frobe, Ana
    Bajic, Zarko
    Vrdoljak, Eduard
    JOURNAL OF ONCOLOGY, 2020, 2020
12345